Immuneering Co. (NASDAQ:IMRX) Expected to Announce Quarterly Sales of $220,000.00

Equities analysts forecast that Immuneering Co. (NASDAQ:IMRXGet Rating) will announce sales of $220,000.00 for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Immuneering’s earnings, with estimates ranging from $190,000.00 to $300,000.00. Immuneering posted sales of $660,000.00 during the same quarter last year, which would suggest a negative year over year growth rate of 66.7%. The firm is scheduled to announce its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Immuneering will report full-year sales of $740,000.00 for the current fiscal year, with estimates ranging from $570,000.00 to $1.00 million. For the next financial year, analysts anticipate that the business will report sales of $800,000.00. Zacks’ sales averages are a mean average based on a survey of research analysts that that provide coverage for Immuneering.

Immuneering (NASDAQ:IMRXGet Rating) last issued its quarterly earnings results on Thursday, March 10th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.03). The business had revenue of $0.19 million during the quarter, compared to analysts’ expectations of $0.60 million.

IMRX has been the topic of several recent analyst reports. Zacks Investment Research raised Immuneering from a “hold” rating to a “buy” rating and set a $4.75 price target on the stock in a research note on Wednesday. Oppenheimer started coverage on Immuneering in a research note on Thursday, March 31st. They issued an “outperform” rating and a $25.00 price target on the stock. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $29.13.

In related news, Director Ann E. Berman purchased 6,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 15th. The stock was acquired at an average price of $6.40 per share, for a total transaction of $38,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have purchased 10,900 shares of company stock valued at $73,621 in the last quarter.

A number of large investors have recently made changes to their positions in the business. UBS Group AG purchased a new stake in shares of Immuneering during the 3rd quarter valued at $30,000. Citigroup Inc. purchased a new stake in shares of Immuneering during the 3rd quarter valued at $33,000. New York State Common Retirement Fund purchased a new stake in shares of Immuneering during the 3rd quarter valued at $45,000. Metropolitan Life Insurance Co NY purchased a new stake in shares of Immuneering during the 3rd quarter valued at $75,000. Finally, JPMorgan Chase & Co. increased its position in shares of Immuneering by 119.5% during the 1st quarter. JPMorgan Chase & Co. now owns 11,969 shares of the company’s stock valued at $78,000 after purchasing an additional 6,515 shares during the last quarter. Hedge funds and other institutional investors own 47.41% of the company’s stock.

Shares of IMRX opened at $5.05 on Friday. Immuneering has a 52-week low of $4.11 and a 52-week high of $33.99. The business’s 50 day moving average price is $6.44 and its two-hundred day moving average price is $13.79.

About Immuneering (Get Rating)

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors.

Recommended Stories

Get a free copy of the Zacks research report on Immuneering (IMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Immuneering (NASDAQ:IMRX)

Receive News & Ratings for Immuneering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuneering and related companies with MarketBeat.com's FREE daily email newsletter.